We're doomed we're saved #24

Show notes

Rare or orphan diseases affect only a small percentage of the population and often lack effective treatments. While rare individually, in total, more than 350 million people worldwide live with rare diseases. Many of these are very hard to diagnose, let alone cure, and the rarity of patients challenges the development of novel treatments.

To make the development of drugs for rare diseases more efficient and successful, artificial intelligence (AI) could be an important ally not only for drug makers but also for patients.

In episode 24 of "We’re Doomed, We’re Saved," Andreas Horchler and Louise von Stechow discuss the benefits and challenges of using AI for drug development in rare diseases.

Content and Editing: Louise von Stechow and Andreas Horchler

Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.

Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow

Image: Geranimo via Unsplash

References Background https://www.nature.com/articles/s41431-021-00928-4 https://www.mdpi.com/2227-9059/11/3/887 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947640/

Drug discovery https://www.nature.com/articles/d43747-021-00164-1 https://insilico.com/blog/rare-diseases https://endpts.com/biden-administration-invests-48m-in-ai-ml-platform-to-identify-rare-disease-drugs/

Diagnosis https://www.labiotech.eu/opinion/rare-disease-diagnosis-ai/ https://www.nature.com/articles/d43747-022-00195-2 https://pubmed.ncbi.nlm.nih.gov/32422592/ https://www.nature.com/articles/s41431-024-01604-z

Clinical research https://www.nature.com/articles/s43856-023-00425-3 https://www.nature.com/articles/d41586-024-00753-x https://www.nature.com/articles/s41591-023-02333-4